TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
2.970
+0.040 (1.37%)
At close: Dec 20, 2024, 4:00 PM
3.040
+0.070 (2.36%)
After-hours: Dec 20, 2024, 4:37 PM EST
TScan Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 9.36 | 21.05 | 13.54 | 10.14 | 1.09 | - |
| Revenue Growth (YoY) | -44.71% | 55.52% | 33.47% | 834.65% | - | - |
| Cost of Revenue | 100.4 | 88.15 | 59.82 | 44.95 | 20.58 | 9.44 |
| Gross Profit | -91.04 | -67.1 | -46.28 | -34.81 | -19.49 | -9.44 |
| Selling, General & Admin | 28.43 | 26.35 | 20.35 | 13.83 | 6.74 | 4.77 |
| Operating Expenses | 28.43 | 26.35 | 20.35 | 13.83 | 6.74 | 4.77 |
| Operating Income | -119.47 | -93.46 | -66.64 | -48.64 | -26.23 | -14.21 |
| Interest Expense | -3.72 | -3.76 | -1.18 | - | - | - |
| Interest & Investment Income | 11.88 | 8 | 1.59 | 0.02 | 0.11 | 0.55 |
| Pretax Income | -111.3 | -89.22 | -66.22 | -48.63 | -26.13 | -13.66 |
| Net Income | -111.3 | -89.22 | -66.22 | -48.63 | -26.13 | -13.66 |
| Net Income to Common | -111.3 | -89.22 | -66.22 | -48.63 | -26.13 | -13.66 |
| Shares Outstanding (Basic) | 53 | 48 | 24 | 12 | 1 | 0 |
| Shares Outstanding (Diluted) | 53 | 48 | 24 | 12 | 1 | 0 |
| Shares Change (YoY) | 11.57% | 98.89% | 106.20% | 1173.20% | 137.87% | - |
| EPS (Basic) | -2.09 | -1.87 | -2.75 | -4.17 | -28.52 | -35.47 |
| EPS (Diluted) | -2.09 | -1.87 | -2.75 | -4.17 | -28.52 | -35.47 |
| Free Cash Flow | -110.58 | -64.5 | -70.73 | -58.62 | -7.26 | -13.77 |
| Free Cash Flow Per Share | -2.07 | -1.35 | -2.94 | -5.03 | -7.93 | -35.75 |
| Operating Margin | -1276.07% | -444.00% | -492.32% | -479.65% | -2417.79% | - |
| Profit Margin | -1188.88% | -423.86% | -489.26% | -479.49% | -2408.02% | - |
| Free Cash Flow Margin | -1181.18% | -306.45% | -522.56% | -578.03% | -669.22% | - |
| EBITDA | -114.79 | -88.1 | -61.5 | -45.31 | -25 | -13.69 |
| D&A For EBITDA | 4.68 | 5.36 | 5.14 | 3.33 | 1.23 | 0.52 |
| EBIT | -119.47 | -93.46 | -66.64 | -48.64 | -26.23 | -14.21 |
Source: S&P Capital IQ. Standard template.
Financial Sources.